Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors

BACKGROUND: Multiple myeloma (MM) is still a fatal plasma cell cancer. Novel compounds are currently clinically tested as a single agent in relapsing patients, but in best cases with partial response of a fraction of patients, emphasising the need to design tools predicting drug efficacy. Histone de...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreaux, J, Reme, T, Leonard, W, Veyrune, J-L, Requirand, G, Goldschmidt, H, Hose, D, Klein, B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3739014/
https://www.ncbi.nlm.nih.gov/pubmed/23868005
http://dx.doi.org/10.1038/bjc.2013.392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3739014/
https://www.ncbi.nlm.nih.gov/pubmed/23868005
http://dx.doi.org/10.1038/bjc.2013.392

Ejemplares similares